In this study we identified potentially actionable somatic mutations in metastatic breast tumors using the Ion AmpliSeq™ Cancer Hotspot Panel v2.

Twenty-two cases were sequenced, and 28 variants in 11 of the 50 genes analyzed were observed; an average of 1.7 variants per tumor.

The most commonly altered genes included m>TP53m>, m>PIK3CAm>, m>APCm>, m>METm>, and m>ERBB2m>.

Metastatic breast cancer is genetically diverse and the majority of metastatic breast tumors harbor potentially actionable mutations.

NGS of metastatic breast cancer provides a useful modality to characterize metastatic breast cancer on an individualized basis.